Literature DB >> 21286438

Intraoperative acute brain swelling when performing indirect anastomosis in a patient with moyamoya disease -A case report-.

Ji-Sung Nho1, Soo-Eun Choi, Jae-Woo Yi, Jong-Man Kang.   

Abstract

A 6-year-old male patient who was suffering from a cold and a transient ischemic attack was scheduled to undergo encephalo-duro-arterio-synangiosis for treating his moyamoya disease. Acute brain edema occurred just after opening the dura mater. Head elevation, reduction of the head rotation and hyperventilation were done. The inhalational agents were discontinued and total intravenous anesthesia was started. The swelling was reduced after intravenously infusing mannitol. An abrupt return from hypocapnia to normocapnea during the induction of general anesthesia was thought to be the cause of the acute brain swelling. In conclusion, correction of hypocapnea needs to be performed gradually during the induction of anesthesia and when performing an operation for treating a patient with moyamoya disease.

Entities:  

Keywords:  Brain edema; Cerebral revascularization; Mannitol; Moyamoya disease

Year:  2010        PMID: 21286438      PMCID: PMC3030034          DOI: 10.4097/kjae.2010.59.S.S191

Source DB:  PubMed          Journal:  Korean J Anesthesiol        ISSN: 2005-6419


  11 in total

Review 1.  Moyamoya disease.

Authors:  M Fukui; S Kono; K Sueishi; K Ikezaki
Journal:  Neuropathology       Date:  2000-09       Impact factor: 1.906

2.  Intracerebral steal phenomenon associated with global hyperemia in moyamoya disease during revascularization surgery.

Authors:  H Oshima; Y Katayama; T Hirayama
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

3.  Influence of ischemia and reperfusion on the course of brain tissue swelling and blood-brain barrier permeability in a rodent model of transient focal cerebral ischemia.

Authors:  G Gartshore; J Patterson; I M Macrae
Journal:  Exp Neurol       Date:  1997-10       Impact factor: 5.330

4.  The history of neurosurgical procedures for moyamoya disease.

Authors:  Cassius V C Reis; Sam Safavi-Abbasi; Joseph M Zabramski; Sebastiao N S Gusmão; Robert F Spetzler; Mark C Preul
Journal:  Neurosurg Focus       Date:  2006-06-15       Impact factor: 4.047

5.  Effect of inhalational anesthesia on cerebral circulation in Moyamoya disease.

Authors:  K Sato; R Shirane; M Kato; T Yoshimoto
Journal:  J Neurosurg Anesthesiol       Date:  1999-01       Impact factor: 3.956

Review 6.  [Treatment of acute brain edema].

Authors:  J I Suárez
Journal:  Rev Neurol       Date:  2001 Feb 1-15       Impact factor: 0.870

7.  Risk factors of moyamoya disease in Canada and the USA.

Authors:  S J Peerless
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

8.  Acute intraoperative brain herniation during elective neurosurgery: pathophysiology and management considerations.

Authors:  I R Whittle; R Viswanathan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

9.  Propofol increased cerebral perfusion as compared with isoflurane during a cerebral angiography in a child with moyamoya disease.

Authors:  Xavier Culebras; Jean-Baptiste Martin; Miriam Treggiari-Venzi; Daniel Ruefenacht; Walid Habre
Journal:  J Neurosurg Anesthesiol       Date:  2003-01       Impact factor: 3.956

10.  Local cortical cerebral blood flow and response to carbon dioxide during anesthesia in patients with moyamoya disease.

Authors:  T Yusa; K Yamashiro
Journal:  J Anesth       Date:  1999       Impact factor: 2.078

View more
  2 in total

1.  Mechanism of brain swelling in cases of brain evisceration due to catastrophic craniocerebral injury - an autopsy study.

Authors:  Vladimir Živković; Danica Cvetković; Danilo Obradović; Slobodan Nikolić
Journal:  Forensic Sci Med Pathol       Date:  2020-01-28       Impact factor: 2.007

Review 2.  Progress on Complications of Direct Bypass for Moyamoya Disease.

Authors:  Jinlu Yu; Lei Shi; Yunbao Guo; Baofeng Xu; Kan Xu
Journal:  Int J Med Sci       Date:  2016-07-05       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.